ESMO22: personalized TIL therapy improves PFS by 50% in advanced melanoma

A pioneering treatment paradigm with personalized cell therapy reduces the chance of disease progression and death by 50% in advanced melanoma patients compared to standard immunotherapy. The results of the randomised Phase III M14TIL trial were presented for the first time at ESMO Congress 2022 (9–13 September, Paris, France). Treatment of metastatic melanoma has evolved in the past decade with the development of checkpoint inhibitors, such as the CTLA-4 inhibitor ipilimumab. These immunotherapy drugs block checkpoint proteins that prevent the immune system from targeting and attacking cancer cells. Checkpoint inhibitors are now regularly given as a first-line therapy and demonstrate...